U.S. markets closed
  • S&P Futures

    3,825.75
    -2.25 (-0.06%)
     
  • Dow Futures

    31,335.00
    -36.00 (-0.11%)
     
  • Nasdaq Futures

    12,773.25
    -58.50 (-0.46%)
     
  • Russell 2000 Futures

    2,181.40
    -18.60 (-0.85%)
     
  • Crude Oil

    63.09
    -0.44 (-0.69%)
     
  • Gold

    1,770.70
    -4.70 (-0.26%)
     
  • Silver

    27.42
    -0.27 (-0.98%)
     
  • EUR/USD

    1.2164
    -0.0022 (-0.18%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.3987
    -0.0026 (-0.19%)
     
  • USD/JPY

    106.0800
    -0.1500 (-0.14%)
     
  • BTC-USD

    47,483.80
    -3,256.11 (-6.42%)
     
  • CMC Crypto 200

    945.73
    -48.93 (-4.92%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,375.46
    -792.81 (-2.63%)
     

Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
Editas Medicine, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, August 6, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of 2020.

To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 9185596. A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Investors
Mark

image desc for 52
image desc for 52

Mullikin
(617) 401-9083
mark.mullikin@editasmed.com

Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com